Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/01/24
End: 05/31/27
Due: 05/31/28
Phase: N/A
Priority: Normal
Start: 12/30/23
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 12/30/23
End: 12/31/25
Due: 12/31/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma | NCT06388135 | Yang Jianjun, PhD | user2@example.com | None | 2024-05-01 | 2027-05-31 | 2028-05-31 | - | - | 2025-07-14 |
| Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer | NCT06169410 | Yang Jianjun, PhD | user2@example.com | None | 2023-12-30 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |
| Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric Adenocarcinoma | NCT06192186 | Yang Jianjun, PhD | user2@example.com | None | 2023-12-30 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |